ClinicalTrials.gg
Active, not recruitingNCT05687266AVANZARUpdated Oct 9, 2026

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

A Phase 3 interventional study of Datopotamab deruxtecan and Durvalumab in NSCLC, sponsored by AstraZeneca. Active, not recruiting at 254 sites in 23 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Oct 9, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,350
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 20 under way, 9 of them phase 3. datopotamab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
Largest of 22
1,350 · median 273
Started
2022
with 3 others
Phase 3
9 of 22
3 open now
Primary completion
2027-11
later than 7 of 19 live
Registered
12th of 22
by date
Lead sponsor
12 of 22
AstraZeneca

Among the 22 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment, is one of 4 that started in 2022, is one of 9 in phase 3, reaches primary completion later than 7 of the 19 other live ones, and was the 12th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 22 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).

Read the detailed description

Participants with locally advanced or metastatic NSCLC without actionable tumor tissue genomic alterations and confirmed to meet all eligibility criteria will be randomized in a 1:1 ratio to Dato-DXd in combination with durvalumab and carboplatin versus pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment.

The primary objectives of the study are to demonstrate superiority of Dato-DXd in combination with durvalumab and carboplatin relative to pembrolizumab in combination with platinum-based chemotherapy by assessment of the following:

  1. PFS by BICR in first-line treatment of participants with non-squamous TROP2 biomarker positive locally-advanced or metastatic NSCLC
  2. OS in first-line treatment of participants with non-squamous TROP2 biomarker positive locally-advanced or metastatic NSCLC
  3. PFS by BICR in first-line treatment of participants with non-squamous locally-advanced or metastatic NSCLC
  4. OS in first-line treatment of participants with non-squamous locally-advanced or metastatic NSCLC
03

Conditions studied

  • NSCLC

Keywords

  • Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  • Datopotamab deruxtecan (Dato-DXd, Datroway)
  • Durvalumab (Imfinzi)
  • Carboplatin
  • Chemotherapy
  • Antibody-Drug Conjugate (ADC)
  • Trophoblast cell surface protein 2 (TROP2)
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants ≥ 18 years at screening
  • or cytologically documented NSCLC that at the time of randomisation is Stage IIIB or IIIC disease not amenable to surgical resection or definitive chemoradiation or Stage IV disease
  • Lacks sensitising EGFR tumour tissue mutation and ALK and ROS1 rearrangements and has no documented tumour genomic alterations in NTRK, BRAF, RET, MET or other actionable driver oncogenes with approved and available therapies (actionable genomic alterations).

Testing is not required for tumors with squamous histology, with exceptions.

  • PS of 0 or 1
  • Has adequate bone marrow reserve and organ function within 7 days before randomization

Exclusion criteria

Exclusion:

  • Mixed small-cell lung cancer and NSCLC histology; sarcomatoid variant of NSCLC
  • History of another primary with exceptions
  • Persistent toxicities caused by previous anti-cancer therapy not yet improved to Grade ≤ 1 or baseline, with exceptions.
  • Spinal cord compression or clinically or radiologically active
  • History of .
  • Known active or uncontrolled or C virus infection.
  • Uncontrolled or suspected infection requiring IV antibiotics, antivirals, or antifungals.
  • corneal disease
  • History of non-infectious ILD/pneumonitis that required , has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,350 participants (actual)

Study arms

  • Experimental
    Dato-DXd + Durvalumab + Carboplatin

    Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 1120 mg durvalumab plus carboplatin area under the curve \[AUC\] 5 mg/mL/minute.

    Drug: Datopotamab deruxtecan · Drug: Durvalumab · Drug: Carboplatin

  • Active comparator
    Histologic-specific therapy

    Non-squamous NSCLC participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m2 pemetrexed plus either AUC 5 mg/mL/minute carboplatin or 75 mg/m2 cisplatin. Squamous NSCLC participants will be randomized to receive 200 mg of pembrolizumab plus 200 mg/m2 paclitaxel plus AUC 5 or 6 mg/mL/minute carboplatin.

    Drug: Carboplatin · Drug: Pembrolizumab · Drug: Cisplatin · Drug: Pemetrexed · Drug: Paclitaxel

Interventions

  • Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

    Also known as: Dato-DXd, Datroway

  • Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

    Also known as: MEDI4736, Imfinzi

  • Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

  • Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).

  • Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

  • Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

  • Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) by blinded independent central review (BICR) in the non-squamous TROP2 biomarker positive population

    PFS is defined as time from randomisation until progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) as assessed by BICR, or death due to any cause.

    Time frame: Approximately 3 years

  2. Overall Survival (OS) in the non-squamous TROP2 biomarker positive population

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Approximately 5 years

  3. PFS by BICR in the non-squamous population

    PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause.

    Time frame: Approximately 3 years

  4. OS in the non-squamous population

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Approximately 5 years

Secondary outcomes

  1. PFS by BICR in ITT and TROP2 biomarker-defined populations

    PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause.

    Time frame: Approximately 3 years

  2. OS in ITT and TROP2 biomarker-defined populations

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Approximately 5 years

  3. Objective Response Rate (ORR) in ITT, non-squamous and TROP2 biomarker-defined populations

    ORR is defined as the proportion of participants who have a confirmed Complete Response (CR) or confirmed Partial Response (PR), as determined by BICR per RECIST 1.1.

    Time frame: Approximately 5 years

  4. Duration of Response (DoR) in ITT, non-squamous and TROP2 biomarker-defined populations

    DoR is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR and investigator clinical assessment or death due to any cause.

    Time frame: Approximately 5 years

  5. PFS by investigator in ITT, non-squamous and TROP2 biomarker-defined populations

    PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator clinical assessment, or death due to any cause.

    Time frame: Approximately 3 years

  6. Pharmacokinetics of Dato-DXd when combined with durvalumab and carboplatin.

    Concentration of Dato-DXd, total anti-TROP2 antibody, and DXd (payload deruxtecan) in plasma and pharmacokinetic (PK) parameters (such as peak and trough concentrations, as data allow; sparse sampling).

    Time frame: Approximately 5 years

  7. Anti-Drug Antibody (ADA) for Dato-DXd

    The immunogenicity of Dato-DXd when combined with durvalumab and carboplatin.

    Time frame: Approximately 5 years

  8. Time to Second Progression or Death (PFS2) in ITT, non-squamous and TROP2 biomarker-defined populations

    PFS2 is defined as the time from randomisation to the earliest of the progression events (following the initial progression), subsequent to first subsequent therapy, or death.

    Time frame: Approximately 5 years

  9. Clinical Outcome Assessments in ITT, non-squamous and TROP2 biomarker-defined populations

    Clinical Outcome Assessments, such as TTD in pulmonary symptoms (dyspnoea, cough and chest pain) as measured by the NSCLC-SAQ, and TTD in physical functioning as measured by PROMIS Physical Function short form 8c

    Time frame: Approximately 5 years

Other outcomes

  1. Safety of Dato-DXd in combination with durvalumab and carboplatin

    Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE Version 5.0).

    Time frame: Approximately 5 years

07

Study locations

254 sites
  • Research Site
    Phoenix, Arizona 85054, United States
  • Research Site
    Tucson, Arizona 85704, United States
  • Research Site
    Hot Springs, Arkansas 71913, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Springdale, Arkansas 72762, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Boulder, Colorado 80303, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Hinsdale, Illinois 60521, United States
  • Research Site
    Fort Wayne, Indiana 46845, United States
  • Research Site
    Bettendorf, Iowa 52722, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Waukee, Iowa 50263, United States
  • Research Site
    Baton Rouge, Louisiana 70808, United States
  • Research Site
    Covington, Louisiana 70433, United States
  • Research Site
    Duluth, Minnesota 55805, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Hannibal, Missouri 63401, United States
  • Research Site
    Lincoln, Nebraska 68506, United States
  • Research Site
    Lincoln, Nebraska 68516, United States
  • Research Site
    Clifton Park, New York 12065, United States
  • Research Site
    Asheville, North Carolina 28806, United States
  • Research Site
    Canton, Ohio 44710, United States
  • Research Site
    Columbus, Ohio 43219, United States
  • Research Site
    Maumee, Ohio 43537, United States
  • Research Site
    Tulsa, Oklahoma 74134, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Salem, Oregon 97301, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    York, Pennsylvania 17403, United States
  • Research Site
    Watertown, South Dakota 57201, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Irving, Texas 75063, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Henrico, Virginia 23229, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Renton, Washington 98055, United States
  • Research Site
    Spokane, Washington 99202, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Appleton, Wisconsin 54911, United States
  • Research Site
    La Crosse, Wisconsin 54601, United States
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Rankweil, 6830, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Vienna, 1210, Austria
  • Research Site
    Blumenau, 89010-340, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Fortaleza, 60336-045, Brazil
  • Research Site
    Londrina, 86015-520, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 01327-001, Brazil
  • Research Site
    São Paulo, 01509-900, Brazil
  • Research Site
    São Paulo, 09323-900, Brazil
  • Research Site
    Taubaté, 12030-200, Brazil
  • Research Site
    Vitória, 29043-260, Brazil
  • Research Site
    Sofia, 1113, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Varna, 9010, Bulgaria
  • Research Site
    Saint John, New Brunswick E2L 4L2, Canada
  • Research Site
    Brampton, Ontario L6R 3J7, Canada
  • Research Site
    Greater Sudbury, Ontario P3E 5J1, Canada
  • Research Site
    Kitchener, Ontario N2G 1G3, Canada
  • Research Site
    Newmarket, Ontario L3Y 2P9, Canada
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Montreal, Quebec H4J 1C5, Canada
  • Research Site
    Saint-Jérôme, Quebec J7Z 5T3, Canada
  • Research Site
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Research Site
    Beijing, 100010, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100037, China
  • Research Site
    Beijing, 100039, China
  • Research Site
    Beijing, 100853, China
  • Research Site
    Beijing, CN-100730, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Chongqing, 400037, China
  • Research Site
    Guangzhou, 510000, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Jinan, 250021, China
  • Research Site
    Kunming, 650101, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Liuzhou, 545006, China
  • Research Site
    Shandong, China
  • Research Site
    Shanghai, 200030, China

Showing the first 100 of 254 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Nov 2027, 58 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 58 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2022
First posted
Jan 18, 2023
StartActual
Dec 29, 2022
Primary completionEst.
Nov 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Research Site · Sakai, Japan
Show 1 removed
  • Research Site · Osakasayama-shi, Japan
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    1 site added, 1 site removed
    Show site
    • Research Site · Sakai, Japan
    Show 1 removed
    • Research Site · Osakasayama-shi, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05687266
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 18, 2023
Start date
Dec 29, 2022
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Charu Aggarwal
study chair · Perelman Center for Advanced Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion